Genovate Biotechnology

4130

The current Genovate Biotechnology (4130) market capitalization is approximately NT$3.94B, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, Genovate Biotechnology's market cap fluctuates with changes in its share price and share count. Last updated: March 7, 2026 at 9:05 PM Eastern Time

In the most recently reported quarter, Genovate Biotechnology (4130) generated NT$119.40M in revenue, representing a +1.00% year over year change. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: May 7, 2026 at 5:39 AM Eastern Time

In the most recently reported fiscal year, Genovate Biotechnology (4130) generated net income of NT$11.68M, compared with NT$25.70M in the prior fiscal year, representing a -54.54% year over year change. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: May 7, 2026 at 5:39 AM Eastern Time

According to its latest quarterly filing, Genovate Biotechnology (4130) reported EBITDA of NT$1.87M, representing a +2868.25% year over year change. EBITDA is a non-GAAP measure and does not account for depreciation, amortization, interest expense, taxes, or capital expenditures. As a result, it should be considered alongside other financial metrics when assessing operating performance. Actual results may differ from estimates as company-specific or macroeconomic conditions evolve. Last updated: May 7, 2026 at 5:39 AM Eastern Time

As of the most recent reporting period, the company's debt-to-equity ratio stands at 0.00x, calculated as total debt divided by total shareholders' equity. A lower debt-to-equity ratio generally indicates a more conservative capital structure with less reliance on external borrowing, while a higher ratio suggests greater financial leverage and potentially higher sensitivity to interest rates, refinancing conditions, and earnings volatility. The debt-to-equity ratio should be interpreted in the context of the company's industry, business model, cash flow stability, and balance sheet composition. Last updated: May 7, 2026 at 5:39 AM Eastern Time

Based on the latest available data, Genovate Biotechnology (4130) is currently trading at a last twelve months (LTM) P/E ratio of 285.12x. The P/E ratio reflects how much investors are willing to pay today for a dollar of earnings and can vary meaningfully over time due to changes in profitability, growth expectations, margin outlook, and earnings volatility. Last updated: May 8, 2026 at 2:49 AM Eastern Time

Genovate Biotechnology (4130) is currently scheduled to report its next earnings results on May 6, 2026. Earnings dates are subject to change and may be updated by the company with limited notice. Investors typically monitor upcoming earnings releases closely, as they can result in increased volatility depending on reported results, forward guidance, and management commentary. Last updated: March 7, 2026 at 9:05 PM Eastern Time

In the most recently reported quarter, Genovate Biotechnology (4130) revenue was NT$119.40M. Earnings per share (EPS) for the quarter were NT$-0.04. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: 👉 Estimates vs. Actuals Last updated: May 7, 2026 at 5:39 AM Eastern Time

Based on the latest available analyst coverage, Genovate Biotechnology (4130) currently carries a not available consensus rating. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: May 8, 2026 at 2:49 AM Eastern Time

Like other publicly traded stocks, Genovate Biotechnology (4130) shares are bought and sold on stock exchanges such as TPEX and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for Genovate Biotechnology (4130) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add 4130 to your watchlist.

Genovate Biotechnology trades under the ticker symbol 4130 on the TPEX stock exchange. The ticker 4130 is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

As of the most recently reported period, Genovate Biotechnology (4130) employs approximately 194 people worldwide. Reported employee figures may fluctuate over time due to hiring activity, restructuring, automation initiatives, or changes in business strategy. Headcount data is typically disclosed in company filings and reflects full-time employees unless otherwise stated. Last updated: March 7, 2026 at 9:05 PM Eastern Time

Genovate Biotechnology (4130) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest Genovate Biotechnology (4130) stock peers based on overlapping products, services, and competitive dynamics:Tien Liang BioTech (4127)Lactose (India) (524202)Foresee Pharmaceuticals (6576)Oscotec (A039200)Johnson Chemical Pharmaceutical Works (4747)Antengene Corporation (6996)Sunny Pharmtech (6676)Easywell Biomedicals (1799) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to Genovate Biotechnology.